(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Post-Traumatic Stress Disorder
Queen's UniversitySmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Post-Traumatic Stress Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sertraline Yang I. Pachankis, PhD | Phase 4 | BB |
Paroxetine University of Washington | Phase 4 | BB |
Cipralex New York State Psychiatric Institute | Phase 4 | BB |
Methylphenidate VA Office of Research and Development | Phase 4 | BB |
Midomafetamine MAPS Europe B.V. | Phase 2 | B |
View all 39 →
Same molecule, other indications
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →